Calithera Biosciences Announces Update on Complete Liquidation and Dissolution
Calithera Biosciences cancels special meeting of stockholders
Positive
Calithera Biosciences has cancelled its special meeting of stockholders, which was intended to approve the Company’s Plan of Complete Liquidation and Dissolution. The cancellation indicates that the Company was unable to achieve a quorum of stockholders for the meeting.
06/29/2023 - 04:01 PM
Cancels Special Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a quorum of stockholders at its special meeting of stockholders scheduled to be held on June 29, 2023 (the “Special Meeting”), for the purpose of approving the Company’s Plan of Complete Liquidation and Dissolution. In January 2023, the Company announced its intention to commence an orderly wind down of the Company’s business and operations. After consulting with its proxy solicitation advisors, the Company concluded that further attempts to solicit proxies for the Special Meeting would in all likelihood not allow it to achieve a quorum, and as a result has cancelled the Special Meeting.
CONTACT :
Why did Calithera Biosciences cancel its special meeting of stockholders?
Calithera Biosciences cancelled the meeting because it was unable to achieve a quorum of stockholders.
What was the purpose of the special meeting?
The purpose of the special meeting was to approve the Company’s Plan of Complete Liquidation and Dissolution.
What does the cancellation indicate?
The cancellation indicates that the Company was unable to achieve a quorum of stockholders for the meeting.
Calithera Biosciences Inc
CALA Rankings
N/A Ranked by Stock Gains
CALA Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
South San Francisco
About CALA
calithera is focused on discovering and developing first-in-class small molecule drugs that slow tumor growth through controlling key metabolic pathways in the tumor and immune cells. tumor metabolism and tumor immunology are promising new interrelated fields for cancer drug discovery. recent clinical successes have demonstrated the potential to slow abnormal cell growth and create fundamentally new therapies for cancer patients. our investigational onco-metabolism medicines take advantage of the different metabolic requirements of tumor cells and cancer-fighting immune cells. calithera’s discovery and development efforts are focused on solid tumors for which new treatments are urgently needed. we are currently developing our lead candidate in phase 2 trials in patients with renal cell carcinoma, triple negative breast cancer. targeting cancer, differently. our onco-metabolism approach brings an enhanced perspective to cancer.
